Zura Bio - Class A opened lower at $1.41, compared with its previous close of $1.43. In the last trading session, the stock traded between $1.21 and $1.44. It showed a downward intraday trend.
An investment of $100 made 4 years ago in Zura Bio - Class A is now worth
$ 17.06
Resulting in a loss of
$ 82.94 (82.94%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
$-0.20 (-13.64%)
Day High
$1.44
Day Low
$1.21
Day Open
$1.41
Prev Close
$1.43
Volume
32,83,937
1W Return
-69.30%
1M Return
-69.03%
3M Return
-77.77%
6M Return
-74.00%
1Y Return
-72.06%
Market Cap ($ Mn)
119
PE Ratio
-
PB Ratio
2.77
PEG Ratio
-
ROE
-55.30%
ROCE
-55.92%
EPS (TTM)
$-0.27
1 Week
-69.30%
1 Month
-69.03%
3 Months
-77.77%
6 Months
-74.00%
9 Months
-80.27%
Zura Bio shares fall 72% after trial failure; Oppenheimer cuts target to $5
Zura Bio shares dropped approximately 72% after Phase 2 TibuSHIELD trial failure. Oppenheimer maintained Outperform rating but cut price target from $16 to $5. Levi & Korsinsky investigates potential securities law violations regarding late October statements. Trial failed primary endpoint measuring abscess count reduction at Week 16.
TodayZura Bio's Phase 2 hidradenitis suppurativa trial misses primary endpoint
Phase 2 TibuSHIELD study missed primary endpoint for AN count reduction at Week 16. Key secondary endpoints HiSCR50 and HiSCR75 were also not met. Zura Bio is discontinuing tibulizumab development for hidradenitis suppurativa. Safety profile remained consistent with established IL-17 and BAFF inhibition standards. Ongoing trials in systemic sclerosis and polymyalgia rheumatica continue unchanged.
3 days agoZura Bio grants 250,200 inducement stock options to new hires
Granted options for 250,200 Class A Ordinary Shares to five new employees. Exercise price set at $3.56 per share, equal to closing price on October 26, 2026. Awards granted outside the 2023 Equity Incentive Plan under Nasdaq Rule 5635(c)(4). Options vest over four years with 1/4 cliff after one year.
16 days agoZura Bio files prospectus to offer up to $700 million in securities
Zura Bio Limited filed a prospectus with the SEC. The company plans to offer up to $700 million in securities. The filing marks a significant capital market entry.
16 days agoZura Bio Q3 Results: Loss narrows 4.76% YoY to $(0.20) per share
Zura Bio reported a quarterly loss of $(0.20) per share. The result met the analyst consensus estimate. Losses narrowed by 4.76% compared to $(0.21) in the same period last year.
16 days agoZura Bio management to speak at Cantor Global Healthcare Conference
Zura Bio management to hold fireside chat on September 9, 2026. Event takes place at Cantor Global Healthcare Conference in New York. Live webcast available with replay accessible for 30 days. Lead candidate tibulizumab in Phase 2 trials for HS and SSc. NEXUS-PMR study for PMR planned by year-end 2026.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 4 years ago in Zura Bio - Class A is now worth
$ 17.06
Resulting in a loss of
$ 82.94 (82.94%)
Note: Past profits do not guarantee future returns.
